1932

Abstract

Atherosclerotic cardiovascular disease (ASCVD) is associated with significant morbidity and mortality worldwide. Increased serum levels of low-density lipoprotein cholesterol (LDL-C) are an independent risk factor for ASCVD, and clinical trial data have shown that lowering LDL-C generally reduces cardiovascular risk. Until recently, 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors (statins) have been the main therapy for lowering LDL-C. However, some statin-treated patients have persistently elevated residual cardiovascular risk due to inadequate lowering of LDL-C levels or non-LDL-related dyslipidemia. In addition, adverse effects of statins may limit their tolerability and therefore the ability to attain effective doses in some patients. A new class of drugs that inhibit proprotein convertase subtilisin-kexin type 9 (PCSK9) has been developed to treat hyperlipidemia. This review discusses the history and mechanism of action of PCSK9 inhibitors, their metabolic effects, and clinical outcomes associated with these medications, highlighting recent large cardiovascular outcome trials investigating these therapies.

Loading

Article metrics loading...

/content/journals/10.1146/annurev-med-042716-091351
2018-01-29
2024-04-15
Loading full text...

Full text loading...

/deliver/fulltext/med/69/1/annurev-med-042716-091351.html?itemId=/content/journals/10.1146/annurev-med-042716-091351&mimeType=html&fmt=ahah

Literature Cited

  1. Benjamin EJ, Blaha MJ, Chiuve SE. 1.  et al. 2017. Heart disease and stroke statistics—2017 update: a report from the American Heart Association. Circulation 135:e146–e603 [Google Scholar]
  2. Stone NJ, Robinson JG, Lichtenstein AH. 2.  et al. 2014. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 129:S1–45 [Google Scholar]
  3. Silverman MG, Ference BA, Im K. 3.  et al. 2016. Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis. JAMA 316:1289–97 [Google Scholar]
  4. Collins R, Reith C, Emberson J. 4.  et al. 2016. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet 388:2532–61 [Google Scholar]
  5. Boden WE, Probstfield JL, Anderson T. 5.  et al. 2011. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N. Engl. J. Med. 365:2255–67 [Google Scholar]
  6. Barter PJ, Caulfield M, Eriksson M. 6.  et al. 2007. Effects of torcetrapib in patients at high risk for coronary events. N. Engl. J. Med. 357:2109–22 [Google Scholar]
  7. Kosmas CE, DeJesus E, Rosario D, Vittorio TJ. 7.  2016. CETP inhibition: past failures and future hopes. Clin. Med. Insights Cardiol. 10:37–42 [Google Scholar]
  8. Cannon CP, Blazing MA, Giugliano RP. 8.  et al. 2015. Ezetimibe added to statin therapy after acute coronary syndromes. N. Engl. J. Med. 372:2387–97 [Google Scholar]
  9. Wong ND, Chuang J, Zhao Y, Rosenblit PD. 9.  2015. Residual dyslipidemia according to low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B among statin-treated US adults: National Health and Nutrition Examination Survey 2009–2010. J. Clin. Lipidol. 9:525–32 [Google Scholar]
  10. Sirimarco G, Labreuche J, Bruckert E. 10.  et al. 2014. Atherogenic dyslipidemia and residual cardiovascular risk in statin-treated patients. Stroke 45:1429–36 [Google Scholar]
  11. Karalis DG, Victor B, Ahedor L, Liu L. 11.  2012. Use of lipid-lowering medications and the likelihood of achieving optimal LDL-cholesterol goals in coronary artery disease patients. Cholesterol 2012:861924 [Google Scholar]
  12. Seidah NG, Benjannet S, Wickham L. 12.  et al. 2003. The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation. PNAS 100:928–33 [Google Scholar]
  13. Abifadel M, Rabes JP, Devillers M. 13.  et al. 2009. Mutations and polymorphisms in the proprotein convertase subtilisin kexin 9 (PCSK9) gene in cholesterol metabolism and disease. Hum. Mutat. 30:520–29 [Google Scholar]
  14. Abifadel M, Varret M, Rabes JP. 14.  et al. 2003. Mutations in PCSK9 cause autosomal dominant hyper-cholesterolemia. Nat. Genet. 34:154–56 [Google Scholar]
  15. Timms KM, Wagner S, Samuels ME. 15.  et al. 2004. A mutation in PCSK9 causing autosomal-dominant hypercholesterolemia in a Utah pedigree. Hum. Genet. 114:349–53 [Google Scholar]
  16. Burke AC, Dron JS, Hegele RA, Huff MW. 16.  2017. PCSK9: Regulation and target for drug development for dyslipidemia. Annu. Rev. Pharmacol. Toxicol. 57:223–44 [Google Scholar]
  17. Maxwell KN, Breslow JL. 17.  2004. Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype. PNAS 101:7100–5 [Google Scholar]
  18. Park SW, Moon YA, Horton JD. 18.  2004. Post-transcriptional regulation of low density lipoprotein receptor protein by proprotein convertase subtilisin/kexin type 9a in mouse liver. J. Biol. Chem. 279:50630–38 [Google Scholar]
  19. Cohen J, Pertsemlidis A, Kotowski IK. 19.  et al. 2005. Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. Nat. Genet. 37:161–65 [Google Scholar]
  20. Cohen JC, Boerwinkle E, Mosley TH Jr., Hobbs HH. 20.  2006. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N. Engl. J. Med. 354:1264–72 [Google Scholar]
  21. Bergeron N, Phan BA, Ding Y. 21.  et al. 2015. Proprotein convertase subtilisin/kexin type 9 inhibition: a new therapeutic mechanism for reducing cardiovascular disease risk. Circulation 132:1648–66 [Google Scholar]
  22. Seidah NG, Zuhier A, Chetien M, Mbikay M. 22.  2014. PCKS: a key modulator of cardiovascular health. Circ. Res. 114:1022–36 [Google Scholar]
  23. Rashid S, Tavori H, Brown PE. 23.  et al. 2014. Proprotein convertase subtilisin kexin type 9 promotes intestinal overproduction of triglyceride-rich apolipoprotein B lipoproteins through both low-density lipoprotein receptor-dependent and -independent mechanisms. Circulation 130:431–41 [Google Scholar]
  24. Sible AM, Nawarskas JJ, Anderson JR. 24.  2016. PCSK9 inhibitors: an innovative approach to treating hyperlipidemia. Cardiol. Rev. 24:141–52 [Google Scholar]
  25. Dias CS, Shaywitz AJ, Wasserman SM. 25.  et al. 2012. Effects of AMG 145 on low-density lipoprotein cholesterol levels: results from 2 randomized, double-blind, placebo-controlled, ascending-dose phase 1 studies in healthy volunteers and hypercholesterolemic subjects on statins. J. Am. Coll. Cardiol. 60:1888–98 [Google Scholar]
  26. Stein EA, Mellis S, Yancopoulos GD. 26.  et al. 2012. Effect of a monoclonal antibody to PCSK9 on LDL cholesterol. N. Engl. J. Med. 366:1108–18 [Google Scholar]
  27. Mitchell T, Chao G, Sitkoff D. 27.  et al. 2014. Pharmacologic profile of the Adnectin BMS-962476, a small protein biologic alternative to PCSK9 antibodies for low-density lipoprotein lowering. J. Pharmacol. Exp. Ther. 350:412–24 [Google Scholar]
  28. Fitzgerald K, Frank-Kamenetsky M, Shulga-Morskaya S. 28.  et al. 2014. Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial. Lancet 383:60–68 [Google Scholar]
  29. Blom DJ, Hala T, Bolognese M. 29.  et al. 2014. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. N. Engl. J. Med. 370:1809–19 [Google Scholar]
  30. Sabatine MS, Giugliano RP, Keech AC. 30.  et al. 2017. Evolocumab and clinical outcomes in patients with cardiovascular disease. N. Engl. J. Med. 376:1713–22 [Google Scholar]
  31. Koren MJ, Scott R, Kim JB. 31.  et al. 2012. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study. Lancet 380:1995–2006 [Google Scholar]
  32. Giugliano RP, Desai NR, Kohli P. 32.  et al. 2012. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study. Lancet 380:2007–17 [Google Scholar]
  33. Sullivan D, Olsson AG, Scott R. 33.  et al. 2012. Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial. JAMA 308:1–10 [Google Scholar]
  34. Raal F, Scott R, Somaratne R. 34.  et al. 2012. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial. Circulation 126:2408–17 [Google Scholar]
  35. Raal FJ, Stein EA, Dufour R. 35.  et al. 2015. PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial. Lancet 385:331–40 [Google Scholar]
  36. Stein EA, Honarpour N, Wasserman SM. 36.  et al. 2013. Effect of the proprotein convertase subtilisin/kexin 9 monoclonal antibody, AMG 145, in homozygous familial hypercholesterolemia. Circulation 128:2113–20 [Google Scholar]
  37. Raal FJ, Honarpour N, Blom DJ. 37.  et al. 2015. Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial. Lancet 385:341–50 [Google Scholar]
  38. Koren MJ, Giugliano RP, Raal FJ. 38.  et al. 2014. Efficacy and safety of longer-term administration of evolocumab (AMG 145) in patients with hypercholesterolemia: 52-week results from the Open-Label Study of Long-Term Evaluation Against LDL-C (OSLER) randomized trial. Circulation 129:234–43 [Google Scholar]
  39. 39. Food and Drug Administration. 2015. FDA approves Praluent to treat certain patients with high cholesterol: first in a new class of injectable cholesterol-lowering drugs News release. https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm455883.htm. Accessed Apr. 8, 2015
  40. Robinson JG, Farnier M, Krempf M. 40.  et al. 2015. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N. Engl. J. Med. 372:1489–99 [Google Scholar]
  41. Kereiakes DJ, Robinson JG, Cannon CP. 41.  et al. 2015. Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: the ODYSSEY COMBO I study. Am. Heart J. 169:906–15 [Google Scholar]
  42. Cannon CP, Cariou B, Blom D. 42.  et al. 2015. Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial. Eur. Heart J. 36:1186–94 [Google Scholar]
  43. Bays H, Gaudet D, Weiss R. 43.  et al. 2015. Alirocumab as add-on to atorvastatin versus other lipid treatment strategies: ODYSSEY OPTIONS I randomized trial. J. Clin. Endocrinol. Metab. 100:3140–48 [Google Scholar]
  44. Farnier M, Jones P, Severance R. 44.  et al. 2016. Efficacy and safety of adding alirocumab to rosuvastatin versus adding ezetimibe or doubling the rosuvastatin dose in high cardiovascular-risk patients: the ODYSSEY OPTIONS II randomized trial. Atherosclerosis 244:138–46 [Google Scholar]
  45. Moriarty PM, Parhofer KG, Babirak SP. 45.  et al. 2016. Alirocumab in patients with heterozygous familial hypercholesterolemia undergoing lipoprotein apheresis: rationale and design of the ODYSSEY ESCAPE trial. J. Clin. Lipidol. 10:627–34 [Google Scholar]
  46. Teramoto T, Kobayashi M, Uno K. 46.  et al. 2016. Efficacy and safety of alirocumab in Japanese subjects (phase 1 and 2 studies). Am. J. Cardiol. 118:56–63 [Google Scholar]
  47. Kastelein JJ, Ginsberg HN, Langslet G. 47.  et al. 2015. ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia. Eur. Heart J. 36:2996–3003 [Google Scholar]
  48. Ginsberg HN, Rader DJ, Raal FJ. 48.  et al. 2016. Efficacy and safety of alirocumab in patients with heterozygous familial hypercholesterolemia and LDL-C of 160 mg/dl or higher. Cardiovasc. Drugs Ther. 30:473–83 [Google Scholar]
  49. Ridker PM, Tardif JC, Amarenco P. 49.  et al. 2017. Lipid-reduction variability and antidrug-antibody formation with bococizumab. N. Engl. J. Med. 376:1517–26 [Google Scholar]
  50. Ballantyne CM, Neutel J, Cropp A. 50.  et al. 2015. Results of bococizumab, a monoclonal antibody against proprotein convertase subtilisin/kexin type 9, from a randomized, placebo-controlled, dose-ranging study in statin-treated subjects with hypercholesterolemia. Am. J. Cardiol. 115:1212–21 [Google Scholar]
  51. Ridker PM, Revkin J, Amarenco P. 51.  et al. 2017. Cardiovascular efficacy and safety of bococizumab in high-risk patients. N. Engl. J. Med. 376:1527–39 [Google Scholar]
  52. 52. Pfizer. 2016. Pfizer discontinues global development of bococizumab, its investigational PCSK9 inhibitor News release. http://www.pfizer.com/news/press-release/press-release-detail/pfizer_discontinues_global_development_of_bococizumab_its_investigational_pcsk9_inhibitor
  53. Sahebkar A, Di Giosia P, Stamerra CA. 53.  et al. 2016. Effect of monoclonal antibodies to PCSK9 on high-sensitivity C-reactive protein levels: a meta-analysis of 16 randomized controlled treatment arms. Br. J. Clin. Pharmacol. 81:1175–90 [Google Scholar]
  54. Mihaylova B, Emberson J, Blackwell L. 54.  et al. 2012. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 380:581–90 [Google Scholar]
  55. Everett BM, Smith RJ, Hiatt WR. 55.  2015. Reducing LDL with PCSK9 inhibitors—the clinical benefit of lipid drugs. N. Engl. J. Med. 373:1588–91 [Google Scholar]
  56. Nicholls SJ, Puri R, Anderson T. 56.  et al. 2016. Effect of evolocumab on progression of coronary disease in statin-treated patients: the GLAGOV randomized clinical trial. JAMA 316:2373–84 [Google Scholar]
  57. Sabatine MS, Giugliano RP, Wiviott SD. 57.  et al. 2015. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N. Engl. J. Med. 372:1500–9 [Google Scholar]
  58. Koren MJ, Sabatine MS, Giugliano RP. 58.  et al. 2017. Long-term low-density lipoprotein cholesterol-lowering efficacy, persistence, and safety of evolocumab in treatment of hypercholesterolemia: results up to 4 years from the open-label OSLER-1 extension study. JAMA Cardiol. 2:598–607 [Google Scholar]
/content/journals/10.1146/annurev-med-042716-091351
Loading
/content/journals/10.1146/annurev-med-042716-091351
Loading

Data & Media loading...

  • Article Type: Review Article
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error